CT-P6 was approved by both US FDA and European Commission as a biosimilar to reference trastuzumab (RTZ). Here we report updated long term efficacy and safety.
549 patients with HER2 positive EBC were randomized 1:1 to CT-P6 (n = 271) or RTZ (n = 278) with docetaxel (Cycles 1-4) and 5-fluorouracil, epirubicin and cyclophosphamide (Cycles 5-8). After surgery, patients received CT-P6 or RTZ monotherapy to complete a total of 1 year and were followed up to 3 years from enrollment of the last patient. Stratified Cox regression and Kaplan-Meier methods were used for time to event (TTE) analyses.
528 patients (259 in CT-P6 and 269 in RTZ) were followed up. The median duration of follow-up was 39 months. Overall, the rates of disease-free survival (DFS) and overall survival (OS) were similar between CT-P6 and RTZ in both PPS and ITT set. The number of DFS events (42 [16.3%] in CT-P6 and 36 [13.8%] in RTZ) and OS events (18 [6.6%] in CT-P6 and 18 [6.5%] in RTZ) were comparable in ITT set. Median DFS and OS have not been reached due to an insufficient number of events. The mean LVEF was more than 60% in both groups, and no new cases of heart failure were reported during the follow-up period. Table. Summary of Long Term Efficacy Endpoints 190PPPS ITT set CT-P6 n = 248 RTZ n = 256 CT-P6 n = 258 RTZ n = 261 DFS rate 1 year (95% CI) 0.95 (0.91 – 0.97) 0.96 (0.93 – 0.98) 0.95 (0.91 – 0.97) 0.96 (0.93 – 0.98) 2 years (95% CI) 0.87 (0.81 – 0.90) 0.89 (0.85 – 0.92) 0.87 (0.82 – 0.90) 0.89 (0.85 – 0.93) 3 years (95% CI) 0.82 (0.77 – 0.87) 0.82 (0.75 – 0.88) 0.83 (0.77 – 0.87) 0.83 (0.76 – 0.88) Hazard ratio (95% CI) 1.23 (0.78 – 1.94) 1.23 (0.78 – 1.93) p-value 0.3808 0.3807 CT-P6 n = 248 RTZ n = 256 CT-P6 n = 271 RTZ n = 278 OS rate 1 year (95% CI) 1.00 (1.00 – 1.00) 1.00 (0.97 – 1.00) 0.99 (0.97 – 1.00) 0.99 (0.97 – 1.00) 2 years (95% CI) 0.98 (0.95 – 0.99) 0.98 (0.96 – 0.99) 0.97 (0.93 – 0.98) 0.98 (0.96 – 0.99) 3 years (95% CI) 0.95 (0.91 – 0.97) 0.94 (0.90 – 0.96) 0.93 (0.90 – 0.96) 0.94 (0.90 – 0.96) Hazard ratio (95% CI) 0.87 (0.42 – 1.82) 1.10 (0.57 – 2.13) p-value 0.7181 0.7710
DFS and OS rates and cardiotoxicity at a median follow-up of 39 months support the similarity of CT-P6 and reference trastuzumab in early-stage breast cancer.
NCT02162667.
Celltrion.
Celltrion.
J. Stebbing: Officer / Board of Directors, Editer-in-Chief: Oncogene; Advisory / Consultancy: Celltrion; Advisory / Consultancy: Vor Biopharma; Advisory / Consultancy: Benevolent AI; Officer / Board of Directors: BB Biotech Healthcare Trust; Officer / Board of Directors: Xerion Healthcare. Y. Baranau: Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Novatis. V. Moiseyenko: Speaker Bureau / Expert testimony: AstraZeneca. J. Pikiel: Travel / Accommodation / Expenses: Roche. A. Eniu: Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Celltrion; Research grant / Funding (self): Pfizer. S.J. Lee: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Stock option: Celltrion. M.J. Kim: Full / Part-time employment: Celltrion. S. Kim: Full / Part-time employment: Celltrion. S. Park: Full / Part-time employment: Celltrion. J.H. Bae: Full / Part-time employment: Celltrion. F.J. Esteva: Advisory / Consultancy: Celltrion; Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer. All other authors have declared no conflicts of interest.